NEW YORK (GenomeWeb News) – Compugen today reported that its third-quarter revenues declined to $6,000 from $90,000 year over year, as the firm plans to cut staff and reduce its expenses by 30 percent.
The Tel Aviv, Israel-based drug and biomarker discovery platform developer posted a net loss of $3.3 million, or $.12 per share, a 22 percent increase over a net loss of $2.7 million, or $.09 per share, for the third quarter of 2007.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

The London School of Economics' Daniele Fanelli argues at the Proceedings of the National Academy of Sciences that the reproducibility crisis in science isn't as dire as some say.

A team of researchers in Portugal has examined the genomic basis for racing pigeons' athleticism and navigational skills, finding it's likely polygenic.

Wired reports that diagnostic firms continue to seek, post-Theranos, the ability to diagnose diseases from small amounts of blood.

In Science this week: analysis of DNA from ancient North Africans, and more.